Filtered By:
Condition: Hemorrhagic Stroke
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 361 results found since Jan 2013.

Statins and risk of poststroke hemorrhagic complications
Conclusions: Statin use prior to AIS was not associated with early hemorrhagic complications, irrespective of treatment with thrombolysis. New initiation of statin treatment early after AIS did not affect risk of postacute ICH, but might be associated with reduced mortality.
Source: Neurology - April 24, 2016 Category: Neurology Authors: Scheitz, J. F., MacIsaac, R. L., Abdul-Rahim, A. H., Siegerink, B., Bath, P. M., Endres, M., Lees, K. R., Nolte, C. H., On behalf of the VISTA collaboration Tags: Infarction, Intracerebral hemorrhage ARTICLE Source Type: research

Statin use after intracerebral hemorrhage: a 10‐year nationwide cohort study
ConclusionHydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on recurrent ICH or other components of the composite outcome. Additional studies are required to clarify the biological mechanisms underlying these observations. Statin therapy has demonstrated benefits in ischemic stroke patients, but statin use and intracerebral hemorrhage (ICH) remain a concern. Hydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on rec...
Source: Brain and Behavior - March 31, 2016 Category: Neurology Authors: Shu‐Yu Tai, Feng‐Cheng Lin, Chung‐Yin Lee, Chai‐Jan Chang, Ming‐Tsang Wu, Chen‐Yu Chien Tags: Original Research Source Type: research

Statin use after intracerebral hemorrhage: a 10 ‐year nationwide cohort study
ConclusionHydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on recurrent ICH or other components of the composite outcome. Additional studies are required to clarify the biological mechanisms underlying these observations. Statin therapy has demonstrated benefits in ischemic stroke patients, but statin use and intracerebral hemorrhage (ICH) remain a concern. Hydrophilic statin therapy is associated with a reduced risk of recurrent ICH in post‐ICH patients. The intensity of statin use had no significant effect on rec...
Source: Brain and Behavior - May 12, 2016 Category: Neurology Authors: Shu ‐Yu Tai, Feng‐Cheng Lin, Chung‐Yin Lee, Chai‐Jan Chang, Ming‐Tsang Wu, Chen‐Yu Chien Tags: Original Research Source Type: research

Risk-benefit profile of statin therapy 'may be more positive than expected'
This study showed that providing an effective low-cost statin therapy to 10,000 patients for five years would prevent major cardiovascular events such as heart attacks, strokes and coronary artery bypasses in 1,000 people with preexisting vascular disease, as well as 500 people who are at increased risk but have not yet had a vascular event. By contrast, only 50 to 100 cases of symptomatic adverse events would be expected over the same period, as well as 50 to 100 new cases of diabetes, five cases of myopathy and between five and ten haemorrhagic strokes. Should statins be more widely used? Currently, about six million peo...
Source: Arthritis Research UK - September 8, 2016 Category: Rheumatology Source Type: news

Adverse Effects of Statins
To the Editor In his Viewpoint, Dr Thompson wrote, “Although statins reduce total stroke, they increase the risk of hemorrhagic stroke consistent with the observation that low cholesterol levels are associated with an increase in hemorrhagic stroke.” The statement could be misleading and requires clarification.
Source: JAMA - March 14, 2017 Category: Journals (General) Source Type: research

Strokes, cholesterol and statins: When mortality is an endpoint
The Yi et al. stroke mortality study, with 5.2 million person-years of observation in a representative Korean population cohort with a single baseline total cholesterol (TC) measurement, highlights several important issues [1]. First, the authors note the fact that cholesterol lowering “particularly by statins” does not lower stroke mortality in randomized trials. Second, the fact that 53% of stroke deaths were from hemorrhagic strokes, far surpassing its incidence of about 10–20% in all strokes in many countries [1], and that are mainly nonfatal ischemic strokes.
Source: Atherosclerosis - May 2, 2018 Category: Cardiology Authors: Eddie Vos, Pierre Biron Tags: Correspondence Source Type: research

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Effect of initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral hemorrhage
Intracerebral hemorrhage (ICH) has a higher mortality than ischemic stroke. Statin is beneficial for stroke, but high potency statin treatment has been associated with the risk of hemorrhagic stroke. The aim of this study was to assess the impact of initiating statin therapy after ICH on cardiovascular outcomes.
Source: Atherosclerosis - July 10, 2019 Category: Cardiology Authors: Ming-Shyan Lin, Yu-Sheng Lin, Shih-Tai Chang, Po-Chang Wang, Victor Chien-Chia Wu, Wey-Yil Lin, Chang-Min Chung Source Type: research

Stenting for Symptomatic Intracranial Vertebrobasilar Artery Stenosis in Northeast of China: A Single-Center Study
Conclusion: A high technical success rate of IVBS stenting could be achieved, and the safety was acceptable, whereas Mori C lesions were more vulnerable to endovascular procedure and showed a higher rate of complications than A and B types.
Source: Frontiers in Neurology - February 16, 2021 Category: Neurology Source Type: research

Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
CONCLUSION: Chinese patients with AF and coronary stenting had high mortality and incidence of MACCE. We compiled separate predictive models for all-cause death, IS/STE, MACCE, and major bleeding.PMID:34353224 | DOI:10.1080/00015385.2021.1950367
Source: Acta Cardiologica - August 6, 2021 Category: Cardiology Authors: Jian-Yong Zheng Yi Cao Dong-Tao Li Yi-Gang Qiu Li Zhao Zheng-Ming Xu Yi-Xiong Huang Zhi-Bo Hong Tian-Chang Li Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yu Chen Source Type: research

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research